← Leaderboards
Jixin Dong
University Of Nebraska Medical Center
$5,759,083
Attributed
$5,890,573
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,890,573 · 8
By mechanism
R01$3,685,467 · 2
U54$1,181,047 · 2
P20$545,794 · 2
T32$262,981 · 1
R21$215,284 · 1
Top collaborators
- Jennifer D Black1 shared
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Moorthy P. Ponnusamy$2,721,536
- Ravi Salgia$9,622,551
- William F Elmquist$6,030,767
- Maneesh Jain$6,905,007
- Ram I Mahato$10,713,899
Others in their field
Top investigators on “Regulation”
- Kiyoshi Suyehiro · Iodp Management International, Inc$166,539,344
- David Heimbrook · Leidos Biomedical Research, Inc.$152,164,826
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Nevan J Krogan · University Of California, San Francisco$101,337,442
- Asimah Rafi · Technical Resources Inc$95,881,052
- Richard C Boucher · University Of North Carolina Chapel Hill$83,460,414
Research focus
RegulationCellsSignal PathwayPhosphorylationProteinsPhosphotransferasesMalignant NeoplasmsMediatingPathway InteractionsTherapeutic TargetCancer TypeMolecularMitoticSignal TransductionMitosisAffectMicrotubulesBiochemicalDrug SensitivityCancer TherapyMalignant Breast NeoplasmMalignant Neoplasm Of OvaryClinical TrialsCytotoxicity
Grant awards (17)
Targeting PKR-Bcl2 Signaling to Overcome Paclitaxel Resistance in Ovarian Cancer$880,570
R01 · FY2025 · CA · contact PI
Targeting MARK2-HDAC signaling to overcome paclitaxel resistance in pancreatic cancer$339,852
U54 · FY2025 · CA · contact PI
Cancer Biology Training Program$262,981
T32 · FY2025 · CA
Targeting PKR-Bcl2 Signaling to Overcome Paclitaxel Resistance in Ovarian Cancer$556,553
R01 · FY2024 · CA · contact PI
Targeting MARK2-HDAC signaling to overcome paclitaxel resistance in pancreatic cancer$247,902
U54 · FY2024 · CA · contact PI
Targeting FGFR4 to overcome chemoresistance in ovarian cancer$215,284
R21 · FY2024 · CA · contact PI
Targeting PKR-Bcl2 Signaling to Overcome Paclitaxel Resistance in Ovarian Cancer$405,163
R01 · FY2023 · CA · contact PI
Targeting MARK2-HDAC signaling to overcome paclitaxel resistance in pancreatic cancer$260,950
U54 · FY2023 · CA · contact PI
Targeting PKR-Bcl2 Signaling to Overcome Paclitaxel Resistance in Ovarian Cancer$413,431
R01 · FY2022 · CA · contact PI
Targeting MARK2-HDAC signaling to overcome paclitaxel resistance in pancreatic cancer$332,343
U54 · FY2022 · CA · contact PI
Regulation and Functional Dissection of YAP in Mitosis$285,950
R01 · FY2018 · GM · contact PI
Regulation and Functional Dissection of YAP in Mitosis$285,950
R01 · FY2017 · GM · contact PI
Regulation and Functional Dissection of YAP in Mitosis$285,950
R01 · FY2016 · GM · contact PI
Regulation and Functional Dissection of YAP in Mitosis$285,950
R01 · FY2015 · GM · contact PI
Regulation and Functional Dissection of YAP in Mitosis$285,950
R01 · FY2014 · GM · contact PI
REGULATION AND FUNCTION OF KIBRA IN THE HIPPO SIGNALING PATHWAY$271,936
P20 · FY2011 · RR · contact PI
REGULATION AND FUNCTION OF KIBRA IN THE HIPPO SIGNALING PATHWAY$273,858
P20 · FY2010 · RR · contact PI